ישראל -
עברית -
Ministry of Health
וימובו
astra zeneca israel ltd - esomeprazole as magnesium trihydrate 20 mg; naproxen 500 mg - tablets modified release - naproxen - vimovo is a combination product that contains naproxen and esomeprazole. it is indicated for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis and to decrease the risk of developing gastric ulcers in patients at risk of developing nsaid-associated gastric ulcers.vimovo is not recommended for initial treatment of acute pain because the absorption of naproxen is delayed compared to absorption from other naproxen-containing products.
ישראל -
עברית -
Ministry of Health
וימובו
astra zeneca israel ltd - esomeprazole as magnesium trihydrate 20 mg; naproxen 500 mg - tablets modified release - naproxen - vimovo is a combination product that contains naproxen and esomeprazole. it is indicated for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis and to decrease the risk of developing gastric ulcers in patients at risk of developing nsaid-associated gastric ulcers. vimovo is not recommended for initial treatment of acute pain because the absorption of naproxen is delayed compared to absorption from other naproxen-containing products.
ישראל -
עברית -
Ministry of Health
וימובו
astra zeneca israel ltd - esomeprazole as magnesium trihydrate 20 mg; naproxen 500 mg - tablets modified release - naproxen - vimovo is a combination product that contains naproxen and esomeprazole. it is indicated for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis and to decrease the risk of developing gastric ulcers in patients at risk of developing nsaid-associated gastric ulcers. vimovo is not recommended for initial treatment of acute pain because the absorption of naproxen is delayed compared to absorption from other naproxen-containing products.
ישראל -
עברית -
Ministry of Health
וימפט 10 מ"ג/מ"ל
cts ltd - lacosamide 10 mg / 1 ml - solution for infusion - lacosamide - vimpat is indicated as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalization in patients with epilepsy aged 16 years and older.vimpat solution for infusion is an alternative for patients when oral administration is temporary not feasible.